SCHEMBL23901465

SCHEMBL23901465

Cc1cc(-c2cccs2)nc2c(C(=O)NC(=O)C3CCC(OC(C)C)CC3)ncn12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 2/20 0.39
MAPK14 Q16539 1/20 0.39
DEGS1 O15121 1/20 0.38
KDM4E B2RXH2 8/20 0.36
ALDH1A1 P00352 8/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
RECQL P46063 2/20 0.36
RAB9A P51151 2/20 0.36
NPC1 O15118 1/20 0.34
PKM P14618 1/20 0.34
MEN1 O00255 4/20 0.34
KMT2A Q03164 4/20 0.34
MAPT P10636 3/20 0.34
LMNA P02545 2/20 0.34
HPGD P15428 2/20 0.34
NPSR1 Q6W5P4 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
GAA P10253 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21479286 0.86 GSK3B (0.38) GSK3BMAPK14DEGS1KDM4EALDH1A1
SCHEMBL23901518 0.80 CYP2C9 (0.47) KDM4EALDH1A1SMN1; SMN2RAB9ANPC1
SCHEMBL23901466 0.80 DEGS1 (0.37) DEGS1KDM4E
SCHEMBL23901464 0.70 ALDH1A1 (0.45) GSK3BKDM4EALDH1A1SMN1; SMN2RAB9A
SCHEMBL23901575 0.70 KDM4E (0.39) GSK3BKDM4EALDH1A1SMN1; SMN2RAB9A
SCHEMBL17730360 0.68 ATR (0.41) KDM4EALDH1A1SMN1; SMN2RAB9AMAPT
SCHEMBL23901520 0.67 CD38 (0.42)
SCHEMBL19677962 0.67 RIPK1 (0.40) KDM4EALDH1A1MAPT
SCHEMBL19449383 0.66 RIPK1 (0.50) KDM4ESMN1; SMN2RAB9AMEN1KMT2A
SCHEMBL19449610 0.66 RIPK1 (0.50) KDM4ESMN1; SMN2RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210309661-A1 IMIDAZO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS BIAL - R&D INVESTMENTS, S.A. (PT) 2021-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210309661-A1 IMIDAZO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS GBA1, GAA, GBA2 GSK3B 3660/4885MAPK14 3949/4885DEGS1 3452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.